The MPS asset is definitely not worth in the billions. The best deal I think we can get is in the low hundreds of millions for MPS I and IV combined. Reason being that iPPS will not be a first-line therapy and will have to compliment ERT or BMT.
Instead, there could be considerable value elsewhere for other diseases that utilise the same mechanism of action and dosing regimen, since PAR could easily get label extensions.
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-372
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.0¢ | $154.0K | 756.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 89195 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 22541 | 4 |
View Market Depth
| Last trade - 13.44pm 10/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |